Thanks to visit codestin.com
Credit goes to learninghealthadam.substack.com

Policy and Practice

Policy and Practice

Home
Notes
Archive
About
How The FDA Remade Drug Development
My new article in Asterisk Magazine
 • Adam
FDA is asking for fewer trials. That might be the right call.
How clinical trial progress - and changing economics - made the two-trial standard harder to defend
 • Adam
Why clinical trials are inefficient. And why it matters.
If we want to accelerate biomedical progress, we need to understand the root causes of clinical trial inefficiency.
 • Adam
Risk-based regulation is vague regulation
And vague regulation breeds safetyism
 • Adam
The Badness Police
A Theory of Regulation
 • Adam
A vision for clinical trial abundance
What does clinical trial abundance look like? And what still stands in our way?
 • Adam
The collapse of the FDA
FDA's power comes from its reputation. What happens when that reputation is gone?
 • Adam
Thoughts on FDA's New Commissioner's Priority Review Voucher Program
We need better ways to promote the development of new drugs. Will this help?
 • Adam
Policy and Practice
Policy and Practice
Exploring innovation in health and medicine, and the institutions, incentives, and infrastructure that drive it.

Policy and Practice

AboutArchiveSitemap
© 2026 Adam · Privacy ∙ Terms ∙ Collection notice
Codestin Search App Start your SubstackGet the app
Substack is the home for great culture